Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Eva Mikuskova"'
Autor:
Alexander Egle, Thomas Melchardt, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, Tomáš Papajík, Miriam Ladická, Michael Girschikofsky, Mikuláš Hrubiško, Ulrich Jäger, Daniela Voskova, Martin Pecherstorfer, Eva Králiková, Christina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lukas Weiss, Teresa Magnes, Lisa Pleyer, Anton Klingler, Jiří Mayer, Richard Greil
Publikováno v:
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
Abstract No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing i
Externí odkaz:
https://doaj.org/article/5fbc792402b144bb941d23c116493c05
Autor:
Veronika Nemethova, Petra Mazancova, Boglarka Nemethova, Lucia Uhelska, Andrea Babelova, Michal Selc, Kristina Jakic, Ondrej Mitrovsky, Denisa Myslivcova, Marketa Zackova, Alexandra Poturnayova, Angelika Batorova, Antonia Hatalova, Katarina Slezakova, Lubos Drgona, Iveta Oravcova, Eva Mikuskova, Ludmila Demitrovicova, Andrej Vranovsky, Filip Razga
Publikováno v:
Blood. 140:12995-12996
Autor:
Marcin Wójtowicz, Gianluigi Reda, Robin Foà, Mehmet Turgut, Eugen Tausch, Sebastian Böttcher, Marlies E.H.M. Van Hoef, Thomas Perretti, Jens Kisro, Francesc Bosch, Osman Ilhan, Sue Robinson, Beatrice Mahe, Veronique Leblond, Dzhelil Osmanov, Eva Mikuskova, Stephan Stilgenbauer, Peter Trask
Publikováno v:
British Journal of Haematology
British Journal of Haematology, Wiley, 2021, ⟨10.1111/bjh.17326⟩
Scientia
British Journal of Haematology, Wiley, 2021, ⟨10.1111/bjh.17326⟩
Scientia
Summary The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first‐line (1L; fit and non‐fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36fd119698300a25c003d9a2e6aa91d
Autor:
Osman Ilhan, Stephan Stilgenbauer, Wolfgang Knauf, Thea Morris, Ekaterina Gresko, Eva Mikuskova, Linda Lundberg, Susan Robson, Eugen Tausch, Dariusz Woszczyk, Véronique Leblond, Francesc Bosch, Sebastian Böttcher, Tom Moore, Robin Foà, Christoph Renner
Publikováno v:
Leukemia
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiv
Autor:
Julian Raynov, August Zabernigg, Michael Girschikofsky, Richard Greil, Georgi Mihaylov, Teresa Magnes, Alexander Egle, Lukas Smolej, Eva Králiková, Olga Stehlíková, Liana Gercheva, Jiří Mayer, Lukas Weiss, Emil Spasov, Martin Pecherstorfer, Horst Oexle, Tomas Papajik, Daniela Voskova, Tomas Kozak, Stanislav Palasthy, Mikulas Hrubisko, Andreas L. Petzer, Petra Obrtlikova, Thomas Melchardt, Lisa Pleyer, Anton Klingler, Petra Altenhofer, Johannes Andel, Michael Doubek, Emília Flochová, Eva Mikuskova, Thomas Nösslinger, Miriam Ladická, Sonja Burgstaller, Michael Steurer, Ulrich Jäger, Christina Burcoveanu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing induction
Autor:
Emília Flochová, Eva Mikuskova, Tomas Papajik, Michael Girschikofsky, Jiří Mayer, Liana Gercheva, Petra Altenhofer, Michael Steurer, Ulrich Jäger, Mikulas Hrubisko, August Zabernigg, Georgi Mihaylov, Lukas Smolej, Miriam Ladická, Lisa Pleyer, Sonja Burgstaller, Horst Oexle, Emil Spasov, Michael A. Fridrik, Richard Greil, Julian Raynov, Thomas Nösslinger, Eva Králiková, Olga Stehlíková, Alexander Egle, Cristina Burcoveanu, Martin Pecherstorfer, Thomas Melchardt, Anton Klingler, Stanislav Palasthy, Petra Obrtlikova, Michael Doubek, Tomas Kozak, Andreas L. Petzer, Johannes Andel
Publikováno v:
The Lancet Haematology. 3:e317-e329
Summary Background In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves outcomes compared with chemotherapy alone. In this study we aimed to investigate the potential of
Autor:
Iveta Oravcova, Silvia Cingelova, Szépe P, Eva Mikuskova, Lukáš Plank, Andrea Mlcakova, Michal Mego, Jan Gyarfas, Michaela Leitnerova, Ludmila Demitrovicova, Vanda Mikudova, Lubos Drgona
Publikováno v:
International journal of hematology. 108(5)
Myeloid sarcoma is a rare presentation of acute leukemia as a solid tumor at various extramedullary sites. It may present concurrently, before or after the onset of systemic bone marrow leukemia. Unusual clinical localization may lead to misdiagnosis
Autor:
Marek Trněný, Michal Karas, Imrich Markuljak, Kateřina Machová Poláková, Jaroslava Voglová, Karel Indrak, Jan Mužík, Kyra Michalova, Marie Jarošová, Markéta Marková Šťastná, Vladimir Koza, Zdeněk Ráčil, Kateřina Steinerová, Elena Tóthová, Ľudmila Demitrovičová, Eva Mikuskova, Eva Demečková, Eduard Cmunt, Edgar Faber, Daniela Žáčková, Ladislav Dušek, Dana Dvořáková, Zuzana Michalovičová-Sninská, Hana Klamova, Juraj Chudej, Petr Cetkovský, Jana Moravcová
Publikováno v:
Cancer Medicine. 2:216-225
We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatm
Autor:
Ludmila Demitrovicova, Jana Lesko-Andrascikova, Adriana Kafková, Zuzana Sninská, Eva Mikuskova, Martin Mistrik, Tereza Nečasová, Stanislav Palasthy, Katarina Slezakova, Juraj Chudej, Eva Koritakova, Imrich Markuljak, Natalia Stecova, Elena Tóthová
Publikováno v:
ResearcherID
Introduction: With the onset of tyrosine kinase inhibitors (TKI) to treat patients with CML, the number of patients and overall survival increased and quality of life significantly improved. The basic principle of therapy was also changed, according
Autor:
Eugen Tausch, Christoph Renner, Stephan Stilgenbauer, Eva Mikuskova, Osman Ilhan, Darius Woszczyk, Nicola Tyson, Tom Moore, Francesc Bosch, Robin Foà, Helena Adamis, Véronique Leblonde, Sebastian Böttcher
Publikováno v:
Blood. 126:493-493
Background The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101; GAZYVA/GAZYVARO; G) combined with chlorambucil (Clb) has superior efficacy to Clb monotherapy and to rituximab plus Clb with an acceptable safety profile in pat